140 related articles for article (PubMed ID: 1680990)
1. Serum level of immunosuppressive acidic protein in patients with urological malignancies.
Pu YS; Tsai TC; Chiu TY; Hsieh TS; Chen J; Chen SC; Lin MC; Hsu TC
J Formos Med Assoc; 1991 May; 90(5):498-503. PubMed ID: 1680990
[TBL] [Abstract][Full Text] [Related]
2. [Study of immunosuppressive acidic protein (IAP) in patients with renal cell cancer].
Shibayama T; Nakazono M; Koyama Y; Deguchi N; Baba S; Jitsukawa S; Murai M; Tazaki H
Gan No Rinsho; 1984 May; 30(5):481-6. PubMed ID: 6727048
[TBL] [Abstract][Full Text] [Related]
3. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Ohmura K; Miyao N; Yoshioka M; Iwasawa A
Hinyokika Kiyo; 1991 May; 37(5):467-74. PubMed ID: 1858580
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of immunosuppressive acid protein in genitourinary malignant diseases].
Okada S; Kirime S; Kawasaki T; Kanbara A; Kanehara H; Takasaki N; Miyazaki S; Inai S
Hinyokika Kiyo; 1988 Mar; 34(3):411-8. PubMed ID: 3389287
[TBL] [Abstract][Full Text] [Related]
6. [Study on serum levels of immunosuppressive acidic protein (IAP) as a marker of renal cell carcinoma].
Hoshino M; Fuji K; Kataoka K; Inoue K; Higaki Y; Imamura K
Hinyokika Kiyo; 1989 Oct; 35(10):1647-52. PubMed ID: 2610170
[TBL] [Abstract][Full Text] [Related]
7. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
Alevizopoulos A; Tyritzis S; Leotsakos I; Anastasopoulou I; Pournaras C; Kotsis P; Katsarou O; Alamanis C; Stravodimos K; Constantinides C
Int J Urol; 2017 Feb; 24(2):130-136. PubMed ID: 28004432
[TBL] [Abstract][Full Text] [Related]
8. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
9. Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma.
Pummer K; Pürstner P; Auner HL; Stettner H; Trummer H; Penkoff H; Rauchenwald M
Br J Urol; 1994 Jun; 73(6):612-4. PubMed ID: 8032825
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum immunosuppressive acidic protein following surgery in patients with renal carcinoma.
Ueda T; Yasumasu T; Uozumi J; Naito S
Br J Urol; 1993 Oct; 72(4):409-12. PubMed ID: 8261296
[TBL] [Abstract][Full Text] [Related]
11. Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy.
Araki K; Igarashi T; Tobe T; Mizoguchi K; Suzuki H; Furuya Y; Ichikawa T; Nakatsu HO; Ito H
Urology; 2006 Dec; 68(6):1178-82. PubMed ID: 17141843
[TBL] [Abstract][Full Text] [Related]
12. [Inflammatory reaction and laboratory tests: IAP (immunosuppressive acidic protein)].
Sato T; Sakata Y; Tamura K
Rinsho Byori; 1990 Mar; 38(3):255-9. PubMed ID: 2190023
[TBL] [Abstract][Full Text] [Related]
13. [Studies of the cellular immune response in patients with urinary bladder carcinoma. X. Evaluation of serum IAP and ASP levels].
Nishio S; Ozaki Y; Wada S; Kawakita J; Maekawa M
Hinyokika Kiyo; 1984 Apr; 30(4):449-57. PubMed ID: 6485956
[TBL] [Abstract][Full Text] [Related]
14. Determination of serum total lipid and free N-acetylneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of free N-acetylneuraminic acid as tumour marker.
Laganà A; Pardo-Martínez B; Marino A; Fago G; Bizzarri M
Clin Chim Acta; 1995 Dec; 243(2):165-79. PubMed ID: 8747492
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum immunosuppressive acidic protein for staging renal cell carcinoma: comparison with other tumour markers.
Masuda H; Kurita Y; Suzuki K; Fujita K; Aso Y
Br J Urol; 1997 Jul; 80(1):25-9. PubMed ID: 9240175
[TBL] [Abstract][Full Text] [Related]
16. Serotonin used as prognostic marker of urological tumors.
Jungwirth N; Haeberle L; Schrott KM; Wullich B; Krause FS
World J Urol; 2008 Oct; 26(5):499-504. PubMed ID: 18581119
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W
Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448
[TBL] [Abstract][Full Text] [Related]
18. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
19. Serum level of immunosuppressive acidic protein in haemodialysis patients with or without renal cell carcinoma.
Sasagawa I; Nakada T; Kubota Y; Suzuki H; Sawamura T
Br J Urol; 1994 Apr; 73(4):355-7. PubMed ID: 8199820
[TBL] [Abstract][Full Text] [Related]
20. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
